#HER3DXd - Twitter Hashtag

5 months ago

Great perspective by @GrindaThomas on the #SATEEN and #HER3DXd post-ADC trials, both providing prospective data on TOPO1 ADCs after prior T-DXd. Switching ADC target does not seem to be the answer to overcome resistance, if the payload has a similar mechanism of action. @myESMO

ESMO - Eur. Oncology

@myESMO

5 months ago

#ESMOBreast26: Data from two trials of sequential TOPO1 ADC therapy in metastatic #BreastCancer suggest the emergence of payload cross-resistance, despite differing #MonoclonalAntibody targets, as discussed by @GrindaThomas in the #ESMODailyReporter https://t.co/KTUTISN1Jq

myESMO's tweet photo. #ESMOBreast26: Data from two trials of sequential TOPO1 ADC therapy in metastatic #BreastCancer suggest the emergence of payload cross-resistance, despite differing #MonoclonalAntibody targets, as discussed by @GrindaThomas in the #ESMODailyReporter https://t.co/KTUTISN1Jq https://t.co/WVEDnLRU3m

1

14

5

2

6K

4

28

15

9

4K

Oncology Tube

@oncologytube

about 1 year ago

🚨🔥 New NSCLC HER3-DXd 🌟 BREAKTHROUGH? in resistant cases from HERTHENA-Lung02! 🎉 23% progression risk drop & PFS gains! 👉 https://t.co/nlX7aN2wVc ▶️ Watch on YouTube: https://t.co/v8rRMGKrX6 #NSCLC #HER3DXd #LungCancer #Oncology #ClinicalTrials @n @nlinmd @DonEford @stolaney1 @DrJNaidoo @itsnot_pink @DFCI_BreastOnc @aftimosp @drsarahsam @JaniceTNBCmets @RenoHemonc @Debeblab @LungCancerEu @kazuki_nozawa @GuiNaderMarta @PathologyPat @SunnieSKim @anmwongNZ @MarvinSPM @MrugalaMaciej @michelle_li @GaiaGriguolo @JavierDavidBen2 @rishabrama @oncobalaji @guicorreiamd @Hilary_Marie_37 @MaheshIddawela @DrChristinaTeng @WDKhatoun

4

6

2

0

749

Oncology Brothers

@OncBrothers

almost 3 years ago

Post #WCLC23 & #ESMO23 + recent @NCCN updates, in 2024 if all becomes available, for #EGFR 19/21, how are you going to sequence Rx in most pts? Any role of #DatoDxD? #MARIPOSA Ami/Laz #FLAURA2 Osi/Chemo #MARIPOSA2 Ami/Chemo #ATTLAS Chemo/Atezo/Bev #HerthenaLung01 #Her3DxD #lcsm @AD @ADesaiMD @esinghimd @EGFRResisters @JackWestMD @CharuAggarwalMD @RenoHemonc @BijoyTelivala @StephenVLiu @RManochakian @BrunaPellini @Joshua_Reuss #OncTwitter

3

19

4

9

7K

Oncology Brothers

@OncBrothers

about 3 years ago

5. 2L for pts with mEGFR after TKI: a. #CHRYSALIS2: #Amivantamab + #Lazertinib + Chemo, ORR: 50%. High cytopenias. Amivant. Also very active as a single agent in 1st and 2L for #MetExon14 b. #HERTHENALung01: #Her3DXd ADC with activity post TKI. ORR: 30%, mOS ~12 months

OncBrothers's tweet photo. 5. 2L for pts with mEGFR after TKI:

a. #CHRYSALIS2: #Amivantamab + #Lazertinib + Chemo, ORR: 50%. High cytopenias. Amivant. Also very active as a single agent in 1st and 2L for #MetExon14

b. #HERTHENALung01: #Her3DXd ADC with activity post TKI. ORR: 30%, mOS ~12 months https://t.co/qmit1U0lF7

1

11

3

2K

Erika Hamilton, MD, FASCO @ErikaHamilton9

over 4 years ago

Dr. Ian Krop presents #HER3DXd - activity across #TNBC #HR+ and #HER2. ✅PFS 6-8 months depending on subtype with ORR 20-50%. 🫁 ILD 7%, 1 fatal case. #ASCO22 @OncoAlert #bcsm

ErikaHamilton9's tweet photo. Dr. Ian Krop presents #HER3DXd - activity across #TNBC #HR+ and #HER2.

✅PFS 6-8 months depending on subtype with ORR 20-50%.

🫁 ILD 7%, 1 fatal case.

#ASCO22 @OncoAlert #bcsm https://t.co/Tdw8uWqyFB

0

18

5

0

Erika Hamilton, MD, FASCO @ErikaHamilton9

over 4 years ago

@RebeccaDSing discusses 1st abstract from #HER3DXd. One key takeaway with this ADC platform (both TDXd and HER3DXd) is that you don't have to have high expression to benefit. #ESMOBreast22

ErikaHamilton9's tweet photo. @RebeccaDSing discusses 1st abstract from #HER3DXd.

One key takeaway with this ADC platform (both TDXd and HER3DXd) is that you don't have to have high expression to benefit.

#ESMOBreast22 https://t.co/aI2fMhQaw5

0

5

0

1

0

Top Tweets for #HER3DXd

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users